NKG2D-CAR-NK92 cells

Phase 1Biologic

HHenan Medical University

NKG2D-CAR-NK92 cells is one of 47 biologic programs targeting Immunotherapy. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ImmunotherapyRecruiting

ImmunotherapyPhase 1

Recruiting

Competition

Competitive Landscape

76 competitors in Immunotherapy

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 3

21 2

Keytruda

Merck & Co.

Phase 3

16 3

Tecentriq

Roche

Phase 3

8 4

Taxol

Teva

Phase 3

3 5

Paraplatin

AAvyxa

Phase 3

6 6

Yervoy

Bristol-Myers Squibb

Phase 2

8 7

Imfinzi

AstraZeneca

Phase 2

5 8

Herceptin

Roche

Phase 2

4 9

Abraxane

Bristol-Myers Squibb

Phase 2

3 10

Eloxatin

Teva

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Immunotherapy1 trial

NKG2D-CAR-NK92 Cells Immunotherapy for Solid Tumors

Recruiting·HHenan Medical University·Phase 1·NCT05528341·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for NKG2D-CAR-NK92 cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NKG2D-CAR-NK92 cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NKG2D-CAR-NK92 cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Henan Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: HHenan Medical University

NKG2D-CAR-NK92 cells

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Immunotherapy1 trial

References

Drug Info

Quick Facts

Related News